Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer DrugBenzinga • 06/05/25
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceBusiness Wire • 06/04/25
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCOCNBC • 06/03/25
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)Business Wire • 05/31/25
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C MutationsBusiness Wire • 05/30/25
Merck's Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 TrialBusiness Wire • 05/30/25
Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)Seeking Alpha • 05/29/25
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily WithdrawnBusiness Wire • 05/29/25
Merck to Participate in the Bernstein 41st Annual Strategic Decisions ConferenceBusiness Wire • 05/22/25
Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus RashBusiness Wire • 05/21/25